Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$265.9MCash on Hand
146.9mo Cash Runway
Follow ENTX by emailGet an email when ENTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ENTX, unsubscribe in one click. Privacy
📣 What ENTX Says Is Next
in 2027 · “Phase 1 Initiation Planned for 2027: Entera is conducting IND-enabling studies for EB612 in collaboration with OPKO Health (“OPKO”) and plans to initiate a Phase 1 single ascending dose (SAD) study in 2027.”
Company press release, Nov 6, 2026 · SEC filing
second half of 2028 · “Entera is preparing to activate the first clinical site for the Phase 3 study in late 2026, with topline results anticipated in the second half of 2028.”
Company press release, Nov 6, 2026 · SEC filing
late 2026 · “Our team is fully focused on ensuring a seamless trial launch, with expected first site activation in late 2026.”
Company press release, Nov 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Earnings Reported Q3 2026 net loss of $15.6 million, or $0.11 per share, versus $3.2 million a year earlier, driven by a $7.5 million non-cash warrant remeasurement. R&D rose to $4.9 million; cash and equivalents were $265.9 million, with Phase 3 EB613 funding stated through topline results and NDA submission. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 27, 2026 ·
Leadership Entera appointed Dr. Juan Camilo Arjona Ferreira as a Class II director, effective December 1, 2026, and to the compensation committee. Director Haya Taitel is stepping down effective the same date, not over any disagreement. Form 8-K · SEC filing · Press release
Oct 14, 2026 ·
Shareholder vote Entera Bio is asking shareholders to vote at a November 24, 2026 special meeting on eight proposals, five tied to its July 2026 private placement of about $275 million, including a 13,937,915-share increase to its 2018 Equity Incentive Plan and one-time equity grants to its CEO, CFO, COO and Chief of R&D. Form DEF 14A · SEC filing
Oct 6, 2026 ·
Leadership Entera Bio appointed Laura Hamill, a former Gilead and Amgen commercial executive, as a Class I director effective December 1, 2026, joining the audit and corporate governance committees. Director Yonatan Malca will step down effective the same date, not over any disagreement. Form 8-K · SEC filing · Press release
Aug 28, 2026 ·
Financing Entera registered resale of up to 134,803,910 ordinary shares by selling shareholders from a July 28, 2026 private placement, including 11,842,695 shares issuable on pre-funded warrants. The company receives no proceeds. Closing price was $3.08 on August 27, 2026. Form 424B3 · SEC filing
Aug 21, 2026 ·
Financing Registers resale of 134,803,910 ordinary shares by selling shareholders, including 122,961,215 shares and up to 11,842,695 shares issuable on pre-funded warrants, from a July 28, 2026 private placement. The company receives no proceeds from these resales. Shares closed at $3.22 on August 20, 2026. Form S-3 · SEC filing
Aug 18, 2026 ·
Leadership Entera Bio appointed Riccardo Paolo Camisasca, M.D., as Chief Medical Officer, effective immediately, ahead of the planned EB613 Phase 3 initiation. He previously was Global Head of R&D at Sumitomo Pharma Switzerland. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Feb 2026 · Phase 1 · Results Expected · Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo Registry primary completion date, not a results date
Dec 2021 · N/A · Results Expected · Evaluating the Impact of EnteraGam In People With COVID-19 Registry primary completion date, not a results date
Apr 2021 · Phase 2 · Results Expected · A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass Registry primary completion date, not a results date
Dec 2018 · Phase 2 · Results Expected · Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism Registry primary completion date, not a results date
Aug 2017 · Phase 1 · Results Expected · A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects Registry primary completion date, not a results date
Sep 2016 · N/A · Results Expected · Retrospective Study of IBS-D Patients Previously Receiving SBI Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not ENTX's own candidates): Colesevelam, Teriparatide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ENTX holds $265.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $5.4M/quarter from operations,
an estimated runway of 146.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:30 · Moderate
Cash runway 147 months
ATM program on file since Jan 2025 +15
Shelf registration (S-3, May 2025) +10
Company says cash lasts into 2030 -15Based on our current operating plan, we believe that our existing cash resources will be sufficient to fund our planned operations into 2030.10-Q, Nov 2026
Share count 174,137,771 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ENTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.